Skip Navigation
Skip to contents

ACC : Acute and Critical Care

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
2 "Seung-Jae Joo"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Review Article
Cardiology
Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it
Seung-Jae Joo
Acute Crit Care. 2023;38(3):251-260.   Published online August 31, 2023
DOI: https://doi.org/10.4266/acc.2023.00955
  • 44,613 View
  • 2,896 Download
  • 13 Web of Science
  • 15 Crossref
AbstractAbstract PDF
Most of the evidences for beneficial effects of beta-blockers in patients with acute myocardial infarction (AMI) were from the clinical studies published in the pre-reperfusion era when anti-platelet drugs, statins or inhibitors of renin-angiotensin-aldosterone system which are known to reduce cardiovascular mortality of patients with AMI were not introduced. In the reperfusion era, beta-blockers’ benefit has not been clearly shown except in patients with reduced ejection fraction (EF; ≤40%). In the era of the early reperfusion therapy for AMI, a number of patients with mildly reduced EF (>40%, <50%) or preserved EF (≥50%) become increasing. However, because no randomized clinical trials are available until now, the benefit and the optimal duration of oral treatment with beta-blockers in patients with mildly reduced or preserved EF are questionable. Registry data have not showed the association of oral beta-blocker therapy with decreased mortality in survivors without heart failure or left ventricular systolic dysfunction after AMI. In the Korea Acute Myocardial Infarction Registry-National Institute of Health of in-hospital survivors after AMI, the benefit of beta-blocker therapy at discharge was shown in patients with reduced or mildly reduced EF, but not in those with preserved EF, which provides new information about beta-blocker therapy in patients without reduced EF. However, clinical practice can be changed when the results of appropriate randomized clinical trials are available. Ongoing clinical trials may help to answer the unresolved issues of beta-blocker therapy in patients with AMI.

Citations

Citations to this article as recorded by  
  • Finn Waagstein and the paradigm shift in the treatment of heart failure with β-adrenergic receptor antagonists (‘β-blockers’)
    Kristina Lorenz, Ursula Ravens
    Naunyn-Schmiedeberg's Archives of Pharmacology.2026; 399(3): 3133.     CrossRef
  • Chronic β-Blockade and Systemic Homeostasis: Molecular Integration of Cardiorenal and Immune Pathways, a Narrative Review
    Jason Park, Amethyst Hamanaka, Issac Park, Hosam Gharib Abdelhady
    Biomolecules.2025; 15(12): 1653.     CrossRef
  • Beta-Blockers in Patients With Myocardial Infarction: A Meta-Analysis
    Mushood Ahmed, Areeba Ahsan, Aimen Shafiq, Hasan Ahmad, Raheel Ahmed, Jamal S. Rana, Marat Fudim, Gregg C. Fonarow
    American Journal of Therapeutics.2025; 32(4): e351.     CrossRef
  • Neuroimmune Interactions and Their Role in Immune Cell Trafficking in Cardiovascular Diseases and Cancer
    Yutang Wang, Jack C. Anesi, Indu S. Panicker, Darcy Cook, Prapti Bista, Yan Fang, Ernesto Oqueli
    International Journal of Molecular Sciences.2025; 26(6): 2553.     CrossRef
  • Elevated serum amylase concentrations are associated with worse in-hospital outcomes among patients with acute myocardial infarction
    Marijana Mikacic, Marko Kumric, Iva Rancic Vidic, Duska Glavas, Tina Ticinovic Kurir, Josko Bozic, Josip Andelo Borovac
    BMC Cardiovascular Disorders.2025;[Epub]     CrossRef
  • Cardiac arrhythmia following acute myocardial infarction: a retrospective analysis of 27,648 hospitalized patients in a tertiary heart hospital
    Nidal Asaad, Ayman El-Menyar, Rajvir Singh, Betsy Varughese, Shahul Hameed Khan, Hajar AlBinali, Jassim Al Suwaidi
    Monaldi Archives for Chest Disease.2025;[Epub]     CrossRef
  • Beta-Adrenergic Blockers for Acute Myocardial Infarction: 50 years of Expert Opinions in Cecil Textbook of Medicine
    Peter Manu, Gheorghe-Andrei Dan
    American Journal of Therapeutics.2025; 32(3): e274.     CrossRef
  • Prognostic impact of changes in left ventricular ejection fraction and wall motion score index in patients with myocardial infarction
    Min-Wook Bae, Seong-guen Moon, Kyung-Tae Jung, Won-Ho Kim, Sang-Hyun Park, Jihun Ahn, Jin-Yong Hwang, Seok Kyu Oh, Seung Ho Hur, Myung Ho Jung, Kyu-Sun Lee
    Frontiers in Cardiovascular Medicine.2025;[Epub]     CrossRef
  • Identification and Validation of Calcium-Related Diagnostic Markers for Acute Myocardial Infarction via Bioinformatics Analysis and Machine Learning
    Biao Wang, Jianhong Chen, Leili Wang, Yanli Liu, Liu Miao
    International Heart Journal.2025; 66(4): 639.     CrossRef
  • A hypoxia-on-a-chip platform for modeling ischemic arrhythmogenesis and evaluating the effects of levosimendan and OR-1896 on ischemic human iPSC-derived cardiomyocytes
    Mahmoud Gaballah, Kaisla Walls, Fatma Zakzook, Joose Kreutzer, Jouko Levijoki, Katriina Aalto-Setälä
    Frontiers in Bioengineering and Biotechnology.2025;[Epub]     CrossRef
  • In-hospital cardiac arrest after STEMI: prevention strategies and post-arrest care
    Walker Boyd, Wesley Young, Mehmet Yildiz, Timothy D. Henry, Kari Gorder
    Expert Review of Cardiovascular Therapy.2024; 22(8): 379.     CrossRef
  • Association between Inflammation and New-Onset Atrial Fibrillation in Acute Coronary Syndromes
    Ruxandra-Maria Băghină, Simina Crișan, Silvia Luca, Oana Pătru, Mihai-Andrei Lazăr, Cristina Văcărescu, Alina Gabriela Negru, Constantin-Tudor Luca, Dan Gaiță
    Journal of Clinical Medicine.2024; 13(17): 5088.     CrossRef
  • Use of Early Intravenous Beta Blockers in Patients with Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure—Revival or Requiem?
    Azka Latif, Xiaoming Jia
    Cardiovascular Drugs and Therapy.2024; 38(5): 973.     CrossRef
  • Progress in Disease Modeling for Myocardial Infarction and Coronary Artery Disease: Bridging In Vivo and In Vitro Approaches
    Riya Kar, Debabrata Mukhopadhyay, Ramcharan Singh Angom
    Hearts.2024; 5(4): 429.     CrossRef
  • Optimal duration of medical therapy for patients with acute myocardial infarction
    Ki Yung Boo, Seung-Jae Joo, Jae-Geun Lee, Joon-Hyouk Choi, Song-Yi Kim, Geum Ko, Hae Eun Yun, Myung Ho Jeong
    Medicine.2024; 103(48): e40697.     CrossRef
Case Report
Cardiology
A successfully treated case of primary purulent pericarditis complicated by cardiac tamponade and pneumopericardium
Jong Wook Beom, Yeekyoung Ko, Ki Yung Boo, Jae-Geun Lee, Joon Hyouk Choi, Seung-Jae Joo, Ji Hwan Moon, Su Wan Kim, Song-Yi Kim
Acute Crit Care. 2021;36(1):70-74.   Published online October 12, 2020
DOI: https://doi.org/10.4266/acc.2020.00234
  • 14,095 View
  • 211 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDF
Acute pericarditis is caused by various factors, but purulent pericarditis is rare. Primary purulent pericarditis in immunocompetent hosts is very rare in the modern antibiotics era. We report a successfully treated case of primary purulent pericarditis complicated with cardiac tamponade and pneumopericardium in an immunocompetent host. A 69-year-old female was referred from another hospital because of pleuritic chest pain with a large amount of pericardial effusion. She was diagnosed with acute pericarditis accompanied by cardiac tamponade. We performed emergency pericardiocentesis, with drainage of 360 ml of bloody pericardial fluid. The culture grew Streptococcus anginosus, confirming the diagnosis of acute purulent pericarditis. We performed pericardiostomy because cardiomegaly and pneumopericardium were aggravated after removal of the pericardial drainage catheter. The patient received antibiotics for a total of 23 days intravenously and was discharged with oral antibiotic therapy. Purulent pericarditis is one of the rare forms of pericarditis and is lifethreatening. A multimodality approach is required for proper diagnosis and treatment of this disease.

Citations

Citations to this article as recorded by  
  • Pericardial drainage and continuous irrigation for a patient with purulent pericarditis caused by Streptococcus anginosus
    Kazuki Matsumura, Hiroaki Kawano, Takahiro Muroya, Shiro Hata, Hiroki Shinboku, Koichiro Sonoda, Kentaro Furukawa, Koji Maemura
    Journal of Cardiology Cases.2025; 32(2): 62.     CrossRef
  • A Rare Case of Primary Purulent Pericarditis Caused by Streptococcus constellatus
    Medeinė Kapačinskaitė, Dovilė Gabartaitė, Agnė Šatrauskienė, Ieva Sakaitė, Vytė Valerija Maneikienė, Aleksejus Zorinas, Vilius Janušauskas
    Medicina.2023; 59(1): 159.     CrossRef
  • The Clinical View on Streptococcus anginosus Group – Opportunistic Pathogens Coming Out of Hiding
    Magdalena Pilarczyk-Zurek, Izabela Sitkiewicz, Joanna Koziel
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • The effects of pneumopericardium during epicardial catheter ablation after dry pericardiocentesis on patients with ventricular arrhythmia
    Qingyong Chen, Bosen Yang, Zhenggang Lai, Wen Yue, Qing Yang
    Journal of Interventional Cardiac Electrophysiology.2022; 66(2): 373.     CrossRef

ACC : Acute and Critical Care
TOP